Interleukin-2 Receptor-Targeted Therapy by Monoclonal Antibodies in the Rat Corneal Graft

A possible selective therapeutic approach to corneal graft rejection will aim at IL–2 receptor-bearing antigenactivated T-lymphocytes with monoclonal anti IL–2R antibodies. In a rat penetrating keratoplasty model (Lewis x Lewis-BN) comparing to controls (median, 8 days), a significant delay of the a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cornea 1994-09, Vol.13 (5), p.440-446
Hauptverfasser:	Hoffmann, Friedrich, Kruse, Heinrich A, Meinhold, Harald, Bechrakis, Nikolaos E, Heimann, Heinrich, Diamanstein, Tibor
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies, Monoclonal - pharmacokinetics Antibodies, Monoclonal - therapeutic use Cornea - drug effects Cornea - metabolism Cyclosporine - administration & dosage Female Graft Rejection - therapy Immunotherapy Injections, Intraperitoneal Keratoplasty, Penetrating Rats Rats, Inbred BN Rats, Inbred Lew Receptors, Interleukin-2 - immunology Transplantation, Homologous
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A possible selective therapeutic approach to corneal graft rejection will aim at IL–2 receptor-bearing antigenactivated T-lymphocytes with monoclonal anti IL–2R antibodies. In a rat penetrating keratoplasty model (Lewis x Lewis-BN) comparing to controls (median, 8 days), a significant delay of the allograft reaction was achieved by applying a therapeutic dose (15 mg/kg bw) of cyclosporin A (median, 18 days; p
ISSN:	0277-3740 1536-4798
DOI:	10.1097/00003226-199409000-00012